Generic Name: apomorphine hydrochloride
Brand Name: Kynmobi
Manufacturer: Sunovion Pharmaceuticals Canada Inc.
Therapeutic Area: Parkinson’s disease
Indications: Indicated for the acute, intermittent treatment of “OFF” episodes in patients with Parkinson's disease.
Manufacturer Requested Reimbursement Criteria1: Indicated for the acute, intermittent treatment of OFF episodes in patients with Parkinson's disease.
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input open||May 29, 2020|
|Call for patient input closed||July 20, 2020|
- Patient input submission received from The Michael J. Fox Foundation for Parkinsonâs Research, Parkinson Association of Alberta, Parkinson Canada, Parkinson Quebec and Parkinson Society BC (PSBC)
|Submission received||June 25, 2020|
Submission was previously withdrawn and has been refiled by the sponsor
|Submission accepted||July 10, 2020|
|Review initiated||July 13, 2020|
|Draft CADTH review report(s) provided to sponsor for comment||August 28, 2020|
|Deadline for sponsors comments||September 09, 2020|
|CADTH responses on draft review report(s) provided to sponsor||October 08, 2020|
|Expert committee meeting (initial)||October 21, 2020|
|Draft recommendation issued to sponsor||November 04, 2020|
|End of embargo period||November 18, 2020|
- Reconsideration requested
- Target CDEC reconsideration meeting date to be determined